- Since 2019, NSG BioLabs has been a leader in co-working
lab spaces in Singapore, and has
nurtured over 40 biotech companies, of which the startups have
achieved nearly US$400 million
funding in total alongside significant business milestones
- The Eppendorf Group has signed a partnership agreement
with NSG BioLabs to support biotech startups in their R&D
efforts in Singapore
SINGAPORE, June 12,
2024 /PRNewswire/ -- NSG BioLabs, Singapore's largest provider of biotech
co-working laboratory and office space, announces a new partnership
with Eppendorf, a leading international life science company that
develops, manufactures, and distributes instruments, consumables,
and services for use in laboratories around the world, to support
biotech startups by providing needed resources such as product and
applications expertise and its networks to advance startup research
and development (R&D).
Since 2019, NSG BioLabs has been assisting innovators in
creating impactful solutions in the health, biomedical, agrifood,
and industrial biotechnology sectors, working in areas such as
precision medicine, nucleic acids, AI-enabled drug discovery,
synthetic biology, and other impactful areas. With the largest
co-working biotech laboratory and office footprint in Singapore, coupled with extensive networks
with local and international partners, suppliers, and industry
experts, NSG BioLabs has helped over 40 companies as residents. The
company's residents include several multi-billion-dollar
multinationals as well as many promising startups that have
achieved key milestones. The startup residents alone have
successfully raised nearly US$400
million in funding and supported hundreds of jobs.
"We are thrilled to announce our strategic partnership with
Eppendorf, a leader in life sciences equipment and services. At NSG
BioLabs, fostering an environment where our residents can thrive is
our top priority. This collaboration will provide our residents
with exclusive access to Eppendorf's cutting-edge equipment,
consumables, and services, empowering them to accelerate their
research and scale their innovations. Together, we are shaping the
future of life sciences and driving impactful discoveries," said
Daphne Teo, CEO and Founder of
NSG BioLabs
"Empowering innovative biotech startups is of strategic
importance to the Eppendorf Group, as they drive the future of
medical innovation and the development of new treatments.
Eppendorf's purpose is to help improve human living conditions and
we have been clearly committed for almost 80 years in supporting
scientists around the world. Eppendorf is proud to engage in a
partnership with NSG Biolabs, affirming its shared vision for
supporting innovators in creating impactful biotech solutions.
Being part of this scientific community is crucial and this
collaboration will be the catalyst for transformative breakthroughs
in Singapore and beyond," said
Surendran Krishnamurthi, Managing
Director Eppendorf Southeast Asia.
Since its inception, NSG BioLabs has been supporting biotech
startups and multinational companies by providing BSL-2 certified
private and shared laboratory spaces and offices, equipment, as
well as privileged access with service providers and suppliers, and
community engagement. After its first site opening in November 2019, NSG BioLabs expanded with its
second site in August 2021, and
recently in 2023 with its third site. Now, with three sites
totaling 35,000 square feet located in the heart of Singapore's R&D ecosystem, NSG BioLabs
cements its space as a key hub for biotech innovation. As one of
the largest private biotech incubators in the region, coupled with
its strong partnerships and strategic investors, such as Celadon
Partners and ClavystBio, a life sciences investor set up by
Temasek, NSG BioLabs is poised to enhance its value-add offerings
of infrastructure, services, and networks for its growing
community.
About the Eppendorf Group
Eppendorf is a leading international life science company that
develops, manufactures, and distributes instruments, consumables,
and services for use in laboratories around the world.
The product portfolio of the business units Liquid Handling
& Consumables, Separation & Instrumentation and Bioprocess
includes, for example, pipettes, pipette tips, centrifuges, mixers,
ultra-freezers and bioreactors for cell and gene research. In
addition, Eppendorf offers a wide range of high-quality
consumables. In fiscal year 2023, the Eppendorf Group generated
€1.08 billion in sales and invested €69 million in research and
development (R&D).
Eppendorf products are used in academic or industrial research
laboratories, such as pharmaceutical, biotech, chemical, and food
industries, as well as clinical, environmental, forensic, and
industrial laboratories for process analysis, production, and
quality assurance.
Since 1945, the Eppendorf Group has been headquartered in
Hamburg, Germany, and today
operates production and R&D sites in Europe, Asia
and North America and has
subsidiaries in 33 countries. Today, the Group employs more than
5,000 people worldwide. They all act in accordance with the purpose
of the company's founders: to improve human living conditions.
About NSG BioLabs
Founded with a focus on supporting biotech innovation, NSG
BioLabs offers state-of-the-art equipment, efficient operations,
capital efficiency, the expertise of world-class teams and global
networks to assist life sciences companies. The conducive R&D
environment contains fully-equipped, certified BSL-2 laboratory and
office infrastructure across 35,000 sq ft in the prime location of
Biopolis in Singapore.
By providing access to high-quality infrastructure, its
extensive partner network, community, and value-add benefits, NSG
BioLabs ensures that companies, ranging from emerging biotech
startups to multinational companies, can rapidly and efficiently
execute on their cutting-edge research and development ecosystem in
Singapore, leading to the
innovation of revolutionary technologies and products that
translate into breakthrough biotech ventures and impact for
patients.
For more information, visit www.nsgbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nsg-biolabs-and-eppendorf-group-sign-partnership-to-support-biotech-companies-in-singapore-302170850.html
SOURCE NSG BioLabs